ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-L1/4-1BB Bispecific Antibody LBL-024

Its studies are mostly in Carcinoma, Neuroendocrine · Melanoma · Colorectal Neoplasms · Ovarian Neoplasms · Triple Negative Breast Neoplasms, led by Nanjing Leads Biolabs.

Drug pageAnti-PD-L1/4-1BB Bispecific Antibody LBL-024: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jul 17, 202610 company-led studies, 10 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Nanjing Leads Biolabs1010 open or runningphase 3since Jul 17, 2026Nov 17, 2021Dec 2026phase 2 · NCT05170958

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 17, 2021First study: phase 2 study in Advanced Solid TumorFirst studyNCT05170958 · 396 planned · China
  2. Nov 27, 2023Phase 2 study in Advanced Neuroendocrine CarcinomaNCT06157827 · 178 planned · China
  3. Jun 17, 2025Phase 2 study in Ovarian NeoplasmsNCT07042802 · 180 planned · China
  4. Jul 25, 2025Phase 2 study in Advanced MelanomaNCT07099430 · 280 planned · China
  5. Aug 1, 2025Phase 2 study in Advanced Solid TumourNCT07111546 · 140 planned · China
  6. Dec 2, 20252 phase 2 studiesNCT07281976, NCT07331155
  7. Jan 29, 2026Phase 2 study in Advanced Solid TumourNCT07390383 · 110 planned · China
  8. Jul 17, 2026Phase 3 study in Advanced Extrapulmonary Neuroendocrine CarcinomaPhase 3 reachedNCT07720193 · 280 planned · China
  9. Aug 25, 2026Phase 2 study in Colorectal NeoplasmsNCT07791758 · 369 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Advanced Solid TumorNCT05170958
  2. Dec 28, 2026Primary completion: phase 2 study in Advanced Neuroendocrine CarcinomaNCT06157827
  3. Oct 30, 2027Primary completion: phase 2 study in Advanced MelanomaNCT07099430
  4. Dec 25, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT07042802

TargetBeta

“A tetravalent bispecific antibody targeting the immunosuppressive ligand programmed death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) and 4-1BB (CD137; tumor necrosis factor receptor superfamily member 9; TNFRSF9), ”NCIt, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
acasunlimabruleGenmabphase 36
Anti-CD137/PD-L1 Bispecific Antibody FS222Sino Biopharmaceuticalphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07791758Colorectal Neoplasms · China2RecruitingSep 4, 2030369
NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma · China3Not yet recruitingDec 22, 2030280
NCT07390383Advanced Solid Tumour · China2RecruitingMay 30, 2028110
NCT07331155Advanced Solid Tumour · China2RecruitingDec 26, 2028110
NCT07281976Triple Negative Breast Neoplasms · China2RecruitingDec 31, 2027220
NCT07111546Advanced Solid Tumour · China2RecruitingDec 26, 2027140
NCT07099430Advanced Melanoma · China2RecruitingOct 30, 2027280
NCT07042802Ovarian Neoplasms · China2RecruitingDec 25, 2027180
NCT06157827Advanced Neuroendocrine Carcinoma · China2RecruitingDec 28, 2026178
NCT05170958Advanced Solid Tumor · China2RecruitingDec 2026396

How it is read

Names in the registry

  • “LBL-024 for Injection”, 10 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.